ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Explainable Deep Learning of Transcriptomes Prioritizes Candidate Biomarkers With Preferential Performance in Gastric Cardia Cancer Cohorts.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Gastric cardia adenocarcinoma is biologically distinct from distal disease, but deployable molecular markers remain scarce. We investigated whether explainable deep learning applied to public transcriptomes could nominate diagnostic and survival-associated candidates. We developed and externally evaluated an explainable transcriptome-based classifier. The Asian Cancer Research Group SuperSeries GSE66229 (300 tumors and 100 patient-matched non-tumor tissues) underwent robust multi-array average preprocessing and quality control. An attention-based deep neural network was evaluated by stratified fivefold cross-validation for tumor-versus-non-tumor classification. Inputs were restricted before training to genes available in all cohorts and ordered identically; no missing model inputs were imputed. Shapley additive explanations nominated 20 genes, and univariable Cox models evaluated overall survival associations. External testing without refitting used GSE29272 and The Cancer Genome Atlas stomach adenocarcinoma cohort. Pathway analyses provided biological context. Cross-validated receiver operating characteristic and precision-recall areas under the curve were both 1.00. External values were 0.85/0.93 for cardia and 0.50/0.67 for non-cardia in GSE29272, and 0.78/0.80 and 0.71/0.50, respectively, in The Cancer Genome Atlas cohort. Six genes showed nominal survival associations in GSE66229. None replicated statistically in the strict external cardia subset; LVRN and WISP2 were nominally concordant in the full stomach adenocarcinoma cohort, but neither survived six-test correction. Enrichment implicated immune and lipid-related processes. Explainable deep learning prioritized candidates with stronger external performance in cardia-versus-non-tumor contrasts. These exploratory diagnostic and survival findings require clinically adjusted, prospective validation before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.